[Interferon therapy in malignant melanoma].
The incidence of malignant melanoma in the Caucasian population is rising constantly. As mortality rate, also morbidity rate is elevated. Because of better diagnostic tools the curability in early stages is enlarged quantitatively. For high risk cases in stage I and II and metastatic disease there exists no established therapy regimen. Longtime Interferon-alpha therapy as an adjuvant therapeutic tool had shown an improvement of relapse-free interval and survival. The combination of chemotherapeutic regimen and Interferon in the interval resulted in an increase up to 20% success risk.
Kokoschka
E M
EM
Dermatologischen Universitätsklinik Wien.
Micksche
M
M
D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008545:Melanoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate
D016898:Interferon-alpha; D016190:Carboplatin; D002945:Cisplatin
Interferontherapie beim malignen Melanom.